Annovis Bio Stock Soars 10.2% on Bullish Analyst Outlook

Annovis Bio's stock surged 10.2% in pre-market trading on April 23, 2025, reflecting a significant upward momentum.

Analysts have been closely evaluating Annovis Bio's stock, with Maxim Group recently lowering its price target to $70 from $150. This adjustment comes as part of ongoing assessments of the company's performance and market potential.

H.C. Wainwright has maintained its buy rating for Annovis Bio, keeping the target price at $30. This rating underscores the firm's confidence in the company's future prospects, despite recent market fluctuations.

Annovis Bio's consensus target price stands at $37.00, suggesting a substantial upside potential of 2,620.59%. This optimistic outlook is driven by analysts' expectations of significant growth and market opportunities for the company.